Exagen Inc. Form 8-K Summary
Business Context and Reporting Period
Exagen Inc. (XGN), a Delaware corporation, filed this Current Report on Form 8-K on November 19, 2019. The filing reports the entry into a material definitive agreement regarding the company's debt financing structure.
Key Financial Metrics and Debt Terms
The filing details a First Amendment to the Company's Loan and Security Agreement with Innovatus Life Sciences Lending I, LP and other lenders. Key terms include:
- Interest Rate: Reduced to 8.5% annually. This includes a 2.0% paid-in-kind (PIK) component capitalized monthly until December 2022, after which the full 8.5% accrues.
- Maturity Date: Extended to November 19, 2024.
- Interest-Only Period: Extended to December 2022.
- Prepayment Terms: Prepayments are restricted for the initial year following the amendment. A prepayment premium of 3% applies to loans prepaid prior to November 19, 2020, decreasing by 1% annually thereafter.
- Covenants: Interest-only milestones were replaced with a financial covenant requiring the Company to achieve a specified level of revenue on a rolling twelve-month basis, commencing with the quarter ending December 31, 2019.
The filing text does not provide specific values for total revenue, profit, cash flow, or current debt principal balances.
Material Changes
The primary material change is the restructuring of the term loan agreement originally dated September 7, 2017. The amendment lowers the cash interest burden by introducing a PIK component, extends the repayment timeline, and shifts compliance from operational milestones to a revenue-based financial covenant.
Outlook, Risks, and Contingencies
Management Commentary: The Company issued a press release on November 21, 2019, announcing the amendment.
Risks and Contingencies: The new financial covenant introduces a risk of default if the Company fails to meet the specified revenue targets on a rolling twelve-month basis. However, the agreement includes exceptions based on performance milestones and allows for the cure of defaults through the issuance of equity securities or subordinated indebtedness.
Investor Verification Checklist
- Verify the specific revenue threshold required to satisfy the new financial covenant.
- Review the full text of the Loan Amendment (to be filed as an exhibit to the 2019 Form 10-K) for complete prepayment restrictions and cure mechanisms.
- Assess the impact of the 2.0% paid-in-kind interest on the total principal balance and future dilution potential.
- Confirm the Company's current revenue trajectory against the rolling twelve-month requirement starting December 31, 2019.